Risk reduction intervention of cardiovascular disease in China

Submission date 12/10/2012	Recruitment status No longer recruiting	[X] Prospectively registered	
Registration date	Overall study status	[X] Protocol [_] Statistical analysis plan	
19/10/2012	Completed	[X] Results	
Last Edited 05/07/2021	Condition category Circulatory System	Individual participant data	

Plain English summary of protocol

Background and study aims

Cardiovascular disease (CVD, disease of the heart and/or blood vessels) remains one of the main causes of death worldwide. One of the main factors contributing to CVD is raised blood pressure (hypertension), which is responsible for 5 in 10 deaths from coronary heart disease and 6 in 10 deaths from stroke. China has more than 160 million hypertensive patients, and the death rate for stroke is 4-6 times higher than Japan and the USA, while the amount of stroke and hypertension sufferers is far higher in rural areas (country) compared with urban areas (cities). In 2010, an initial study was conducted in two township hospitals of Zhejiang Province, China to understand the latest situation of CVD control and explore the feasibility of a program to lower the risk of CVD. Based on the feedback of this study, we propose to develop and test a package of cardiovascular risk reduction programs in Zhejiang China. The aim of this study is to explore the effectiveness and cost-effectiveness of a comprehensive CVD risk reduction program.

Who can participate?

Adults aged 50-74 years who have high blood pressure and live in the study area.

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group continue to receive standard care for the duration of the study. Those in the second group take part in the CVD risk reduction program. This involves being prescribed a combination of drugs, including anti-hypertensives (drugs which lower blood pressure), low dose aspirin (Which thins the blood and prevents blood clots, lowering the risk of stroke) and a statin (which lowers cholesterol). Participants also receive support for taking their medication properly, attending appointments and making healthy lifestyle changes; and health education (including advice on smoking cessation, reduction of salt, sugar and oil in their diet, and physical exercise). The number of participants to have a CVD event (such as heart attack or stroke) is collected from Zhejiang provincial CVD surveillance system and double checked by interviewing patients at 12, 24 and 36 months. A sampling survey is also conducted at the start of the study and then after 12, 24 and 36 months to find out more about the patients' background, lifestyle and health.

What are the possible benefits and risks of participating?

Participants may benefit from a lower risk of developing CVD. Risks of participating are very low

as the doses of drugs used will be modified on an individual basis. Any negative side effects of the drugs will be closely monitored by family doctors and village doctors.

Where is the study run from? All township hospitals in 3 counties of Zhejiang province, apart from the hospital that took part in the pilot study (China)

When is the study starting and how long is it expected to run for? March 2012 to December 2017

Who is funding the study? 1. Comdis Health Services Delivery Research Consortium (UK) 2. Zhejiang Provincial Centre for Disease Control and Prevention (China)

Who is the main contact? Professor Xiaolin Wei xiaolin.wei@utoronto.ca

Contact information

Type(s) Scientific

Contact name Prof Xiaolin Wei

Contact details

Dalla Lana School of Public Health, University of Toronto 582-155 College Street Toronto Canada M5T 3M7 +1 416 978 2020 xiaolin.wei@utoronto.ca

Type(s)

Scientific

Contact name

Dr Min Yu

Contact details

No. 3399 Binsheng Road Binjiang District Hangzhou China 310051 +86 0571 87115005 myu@cdc.zj.cn

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Cardiovascular disease risk reduction in China: a pilot and clustered randomized controlled trial in Zhejiang

Study objectives

This systematic cardiovascular disease (CVD) risk reduction programme can reduce CVD events of the population in the intervention group compared with the usual care; the programme is cost effective, friendly to implement and scale up.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. University of Leeds Research Ethics Committee, 08/10/2012, ref: HSLTLM/12/010 2. Ethics Committee of Zhejiang Provincial Centre for Disease Control and Prevention, 18/06 /2012

Study design

Prospective open-labeled cluster randomised controlled trial with blinded data analysis

Primary study design

Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Prevention

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Cardiovascular diseases

Interventions

Interventions as of 29/07/2016:

1. Prescribing a combination of drugs: anti-hypertensives, low dose aspirin and a statin;

2. Adherence support on drug compliance, attendance at appointments and healthy lifestyle change;

3. Health education: advice on smoking cessation, reduction of salt, sugar and oil in their diet, and physical exercise.

Previous interventions as of 06/12/2012:

- 1. Prescribing a combination of drugs: anti-hypertensives, low dose aspirin and a statin
- 2. Adherence support for drug compliance, attendance and healthy lifestyle change
- 3. Health Education: smoking cessation, salt, sugar and oil reduction
- 4. Community-based health intervention:
- 4.1. Banners and chalked messages
- 4.2. Peer education by residents with CVD risk
- 5. Implementation strategies, embedded within the primary care delivery system

The intervention will be designed as job descriptions of family doctors and implemented within the primary care delivery system in Zhejiang China

Previous interventions until 06/12/2012:

- 1. Health Education: smoking cessation, salt, sugar and oil reduction
- 2. Proven Drugs: anti-hypertensive's, low dose aspirin, folic acid and a statin
- 3. Adherence support for drug compliance, attendance and healthy lifestyle change
- 4. Implementation strategies, embedded within the primary care delivery system
- The intervention will be designed as job descriptions of family doctors in the rural areas and implemented within the primary care delivery system in rural Zhejiang China

Intervention Type

Mixed

Primary outcome measure

Current primary outcome measure as of 06/12/2012: The major CVD event rates of the residents in study areas

Previous primary outcome measure until 06/12/2012: The percentage of end events in CVD morbidity and mortality

Secondary outcome measures

Current secondary outcome measures as of 29/07/2016:

1. Mean systolic and diastolic blood pressures of participants

2. Time to the first reported CVD event, mortality, and morbidity of CVD events during the trial period of 36 months

3. Mean change in glycated hemoglobin (HbA1c)

4. Mean change in serum TC and low density lipoprotein

5. Adherence to booked appointments, using the denominator of all participants registered, including defaulters

6. Self-reported adherence to drugs and healthy lifestyle change, for example, smoking cessation rates (for participants who smoke at randomization, the percentage who smoke less than one cigarette a week at 24 months after randomization)

7. Cost-effectiveness

8. Feasibility measures

Previous secondary outcome measures until 06/12/2012:

- 1. Mean systolic and diastolic blood pressure
- 2. CVD risk scores
- 3. Prescription rate of intervention drugs

4. Serum total cholesterol, low density lipid cholesterol (LDL)

5. Smoking cessation rates

6. Adherence to booked appointments and self-reported adherence to healthy lifestyle change and drugs

Overall study start date

01/03/2012

Completion date 31/12/2017

Eligibility

Key inclusion criteria

Inclusion criteria as of 29/07/2016: Township hospitals:

1. Have family doctors who provide care according to the essential public health tasks requested by the government and who agree to follow the allocated treatment

2. Are willing to participate in the trial or pilot study

High CVD risk subjects:

1. Adults aged 50-74 years who have provided informed consent

2. Have been diagnosed as hypertension with a calculated 10-year CVD risk of 20% or higher, or have a recorded medical history of diabetes

3. Hold permanent residency in the study area

Previous inclusion criteria as of 06/12/2012: Township hospitals:

1. Have family doctors who provide care according to the essential public health tasks requested by the government and who agree to follow the allocated treatment

2. Are willing to participate in the trial or pilot study

High CVD risk subjects:

1. Adults aged 60 years and above who have provided informed consent

2. Hold permanent residency in the study area

3. Have a calculated 10-year CVD risk of 20% or higher

4. Have a recorded medical history of diabetes, hyperlipidaemia, coronary heart disease, ischaemic or haemorrhagic cerebro-vascular disease, or peripheral vascular disease.

Previous inclusion criteria until 06/12/2012: Township hospitals: 1. Located in rural Zhejiang 2. Have family doctors who provide care according to the essential public health tasks requested

by the government and who agree to follow the allocated treatment

3. Are willing to participate in the trial or pilot study

High CVD risk subjects:

1. Adults aged 40-74 years who have provided informed consent

2. Hold permanent residency in the study area

3. Have a calculated 10-year CVD risk of 20% or higher, including those having a recorded medical history of hypertension (>140/90)

4. Diabetes, hyperlipidaemia, coronary heart disease, ischaemic or haemorrhagiccerebro-vascular disease, or peripheral vascular disease, or those without CVD symptoms.

Participant type(s)

Patient

Age group

Adult

Sex Both

Target number of participants 30,000

Total final enrolment

28130

Key exclusion criteria

Current exclusion criteria as of 06/12/2012:

1. People with known mental illnesses or other severe diseases or disabilities which mean they cannot communicate with township doctors well or regularly

2. Those not living in the community or will move away in the next two years

3. People who have shown serious adverse effects to the recommended drugs

4. Patients who decline to participate in the trial will be excluded

Previous exclusion criteria until 06/12/2012:

1. People with known mental illnesses or other severe diseases or disabilities which mean they cannot communicate with township doctors well or regularly

2. Those not living in the community or will move away in the next three years after recruitment

3. People who have shown serious adverse effects to the recommended drugs

4. Pregnant or breastfeeding women

5. Patients who decline to participate in the trial will be excluded

Date of first enrolment 01/09/2013

Date of final enrolment

31/05/2014

Locations

Countries of recruitment China

Study participating centre Dongguan community health center No.5 Hospital Road Dongguan Street Shangyu District Shaoxing China 312352

Study participating centre

Gaibei Township Hospital Sihe Village Gaibei Town Shangyu District Shaoxing China 312369

Study participating centre Tangpu Township Hospital Xin Street Yangpu Town Shangyu District Shaoxing China

312364

Study participating centre Changtang Township Hospital

No.37 Changtangshang Street Changtang Town Shangyu District Shaoxing China 312352

Study participating centre

Zhangzhen Township Hospital

No.30 Huayuan Road Zhangzhen Town Shangyu District Shaoxing China 312363

Study participating centre

Fenghui Township Hospital Dongmen Community Fenghui Town Shangyu District Shaoxing

China 312361

Study participating centre Yonghe Township Hospital Yonghe village Shangyu District Shaoxing China 312371

Study participating centre Caoe Community Health Center No.301 Lianfeng Road Shangyu District Shaoxing China 312352

Study participating centre Lingnan Township Hospital Fengshuping Village Daoxu Town Shangyu District Shaoxing China 312379

Study participating centre Dingzhai Township Hospital

No.111 Xiaxi Road Shangzhai Town Dingzhai County Shangyu District Shaoxing China 312373

Study participating centre Xiaoyue Township Hospital

No.134 Yuedong Road Xiaoyue Town Shangyu District Shaoxing China 312367

Study participating centre Chenxi Township Hospital

Damiao,Chenxi County Shangyu District Shaoxing China 312362

Study participating centre Shangpu Township Hospital .Shangpu Village Shangpu Town Shangyu District Shaoxing China

312375

Study participating centre

Lianghu Township Hospital Lianghu Nerghborhood Committee Lianghu Town Shangyu District Shaoxing

China 312399

Study participating centre

Songxia Township Hospital No.328 Baisong Road Songxia Town Shangyu District Shaoxing China 312365

Study participating centre Xietang Township Hospital Jinsheng Street Donglian Village Xietang Town Shangyu District Shaoxing China 312369

Study participating centre Baiguan Community Health Center No.137 Mid Renmin Road Baiguan Street Shangyu District Shaoxing China 312399

Study participating centre Yiting Township Hospital Xinyiting Village Yiting Town Shangyu District Shaoxing China 312353

Study participating centre

Xiaguan Township Hospital

No.28 Shuren Road Xiaguan Town Shangyu District Shaoxing China 312351

Study participating centre Sanjie Township Central Hospital No.60 Qingchun Road Sanjie Town Shengzhou Shaoxing China 312452

Study participating centre Tongyuan Township Hospital Gangxia Village Tongyuan County Shengzhou Shaoxing China 312471

Study participating centre Xiawang Township Hospital No.1 Fupai Road Xiawang Village Xiawang Town Shengzhou Shaoxing China 312454

Study participating centre Sanjiang Community Health Center No.32 Shangtang South Road Sanjiang Street Shengzhou Shaoxing China 312499

Study participating centre Shihuang Township Hospital No.1 Zhenxi Road Shihuang Town Shengzhou Shaoxing

China 312471

Study participating centre Shanhu Community Health Center No.23 Donghou Street Shengzhou Shaoxing China 312432

Study participating centre Xianyan Township Hospital Xianyan Village Xianyan Town Shengzhou

Shaoxing China 312459

Study participating centre Lushan Community Health Center No.143 Changan Road Shengzhou Shaoxing China 312499

Study participating centre Gulai Township Hospital No.43 Wenwei Road Shengzhou Shaoxing China 312472

Study participating centre Beizhang Township Hospital Beizhang Village Beizhang Town Shengzhou Shaoxing China 312458

Study participating centre Pukou Community Health Center No.3 Wenhua Road Pukou Street Shengzhou Shaoxing China 312451

Study participating centre Ganlin Township Central Hospital No.2 Damiao Road Shengzhou Shaoxing China 312464

Study participating centre Wangyuan Township Hospital No.289 Wnagyuan Village Wangyuan County Shengzhou Shaoxing China 312472

Study participating centre

Jinting Township Hospital

Jinxi Village Jinting Town Shengzhou Shaoxing China 312458

Study participating centre Guimen Township Hospital Guimen Village Guimen County Shengzhou Shaoxing

China 312466

Study participating centre Zhuxi Township Hospital Zhuxi Village Zhuxi County Shengzhou Shaoxing China 312472

Study participating centre Linan Township Hospital Xiaye Village Linan County Shengzhou Shaoxing China 312465

Study participating centre Huangyi Township Central Hospital Huangze Town Shengzhou Shaoxing China 312455

Study participating centre Yahuang Township Hospital Yahuang Village Yahuang County Shengzhou Shaoxing China 312471

Study participating centre Chongren Township Central Hospital Lingtang Road Chongren Town Shengzhou Shaoxing China 312473

Study participating centre Changle Township Central Hospital Changle Town Shengzhou Shaoxing China 312467

Study participating centre Huangshan Township Hospital No.291 Xiashi Village Huangshan Town Zhuji Shaoxing China 311809

Study participating centre Chenzhai Township Hospital Chen Residence Chenzhai Town

Zhuji Shaoxing

China 311823

Study participating centre Zhibu Township Hospital Zhibu Village

Zhibu Town Zhuji Shaoxing China 311827

Study participating centre Jiangzao Township Hospital Jiangzao Village Jiangzao Town Zhuji Shaoxing China 311822

Study participating centre Zhaojia Township Hospital Zhaojia Town Zhuji Shaoxing China 311819

Study participating centre

Ruanshi Township Hospital No.142 Nanbin Road Ruanshi Town Zhuji Shaoxing China 311826

Study participating centre

Wuxie Township Hospital

No.19 Wuxie Road Wuxie Town Zhuji Shaoxing China 311807

Study participating centre Jiyang Community Health Center No.98 Zhugong Road Zhuji Shaoxing China 311899

Study participating centre Lipu Township Hospital No.102 Shuidong Road Lipu Town Zhuji Shaoxing

China 312300

Study participating centre Paitou Community Health Center Paitou Town Zhuji Shaoxing China 311825

Study participating centre Lingbei Township Hospital No.110 Zhuyuanfang

Lingbei Town Zhuji Shaoxing China 311823

Study participating centre Ciwu Township Hospital

No.13 Xiusong Road Ciwu Town Zhuji Shaoxing China 311815

Study participating centre

Jieting Township Hospital Jieting Village Jieting Town Zhuji Shaoxing China 311805

Study participating centre

Caota Township Hospital No.30 Fuzhou East Road Cao Tower Town Zhuji Shaoxing China 311812

Study participating centre Huandong Community Health Center No 580 Ji East Road Zhuji Shaoxing China 311899

Study participating centre Donghe Township Hospital Dongyi Donghe Town Zhuji

Shaoxing China 311833

Study participating centre Taozhu Community Health Center No.317 County Road Zhuji Shaoxing China 311899

Study participating centre Datang Township Hospital Qingfang North Road Datang Town Zhuji Shaoxing China 311801

Study participating centre Majian Township Hospital

No.5 Majian Town Zhuji Shaoxing China 311803

Study participating centre Anhua Township Hospital

Xin Street Development Area Anhua Town Zhuji Shaoxing China 311821

Study participating centre Yingdian Community Health Center No.7 Jiankang Road Yingdianjie Town Zhuji Shaoxing China 311817

Study participating centre Dongbaihu Township Hospital Chencai Village East Baihu Town Zhuji Shaoxing China 311818

Study participating centre Wangjiajing Township Hospital No.50 Shinan Road Wnagjiajin Town Zhuji Shaoxing China 311813

Study participating centre Shanxiahu Township Hospital Licha Road Shanxiahu Town Zhuji Shaoxing China 311804

Study participating centre Diankou Township Hospital

Diankou Township Hospital No.16 Zhenganxi Road Zhuji Shaoxing China 311835 **Study participating centre Fengqiao Township Hospital** Youyi Plaza Zone Fengqiao Town Zhuji Shaoxing China 311811

Study participating centre Tongshan Township Hospital .No.2 Xin Street Tongshan Town Zhuji Shaoxing China 311808

Sponsor information

Organisation University of Leeds

Sponsor details 101 Clarendon Road Leeds United Kingdom LS2 9LJ

Sponsor type Research organisation

Website http://www.leeds.ac.uk/

ROR https://ror.org/024mrxd33

Organisation Zhejiang Provincial Center for Disease Control

Sponsor details

No. 3399 Binsheng Road Binjiang District Hangzhou China 310051

Sponsor type Government

Website http://www.cdc.zj.cn/

Funder(s)

Funder type University/education

Funder Name Comdis Health Services Delivery Research Consortium

Funder Name Zhejiang Provincial Center for Disease Control

Results and Publications

Publication and dissemination plan

Planned publication of five papers in in high-impact peer reviewed journals:

- 1. Baseline evaluation of medication adherence (to be published during the trial)
- 2. Interim analysis of secondary outcomes (to be published during the trial)

3. Qualitative paper on process evaluation of the trial (to be published about one year after the trial end)

- 4. Paper on costing study (to be published about one year after the trial end)
- 5. Paper on final outcomes of the trial (to be published about one year after the trial end)

Intention to publish date

31/12/2017

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>	protocol	25/10/2013		Yes	No
<u>Results article</u>	results	16/08/2017	26/02/2021	Yes	No
<u>Results article</u>		01/07/2021	05/07/2021	Yes	No